Loading...
•
Sep 30, 2021
Janux Q3 2021 Earnings Report
Reported financial results for the quarter ended September 30, 2021.
Key Takeaways
Janux Therapeutics reported $387.5 million in cash and cash equivalents and short-term investments. The company is on track to submit IND filings for two programs in 2022. Net loss was $10.8 million for the quarter ended September 30, 2021.
Janux remains on-track to submit IND filings for two programs in 2022.
PSMA-TRACTr candidate IND application expected in the first half of 2022.
EGFR-TRACTr candidate IND application expected in the second half of 2022.
Board of Directors strengthened with key appointments.
Janux
Janux
Forward Guidance
Janux expects to submit an IND application for its PSMA-TRACTr candidate in the first half of 2022 and an IND application for its EGFR-TRACTr candidate in the second half of 2022. In 2023, Janux expects to submit an IND application for its TROP2-TRACTr.
Positive Outlook
- TRACTr product candidates advancing as planned.
- On track for selection of TRACIr development candidate in 2022 as planned.
- IND submission for PSMA-TRACTr candidate expected in the first half of 2022.
- IND submission for EGFR-TRACTr candidate expected in the second half of 2022.
- IND submission for TROP2-TRACTr candidate expected in 2023.